Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Real-world data unlocks Ibrance ok in male breast cancerThe FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based Share XReal-world data unlocks Ibrance ok in male breast cancerhttps://pharmaphorum.com/news/real-world-data-unlocks-ibrance-ok-in-male-breast-cancer/
Ibrance approval cemented as competition comes into viewIn February 2015, Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed Share XIbrance approval cemented as competition comes into viewhttps://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
